Loading...

LIXT LIXTE BIOTECHNOLOGY HOLDINGS INC Management Changes 8-K Filing

LXT

LXT

LIXTE BIOTECHNOLOGY HOLDINGS INC

(LIXT)

2025 8-K

Summary

Summary

Digital Currency Purchase

Management Changes

Corporate Update Released

Treasury Policy Update

Regulatory Compliance

Market Expansion

Equity Offerings

Equity Offerings

Convertible Securities

Nasdaq Compliance

New Study Launch

Clinical Update

Clinical Trial Update

Sales Agreement Termination

Clinical Findings

Clinical Trial Update

Nasdaq Compliance

Clinical Trial Update

Earnings Report

Earnings Report

Annual Meeting Results

Clinical Trial Update

Earnings Report

Earnings Report

Earnings Report

Quantitative Data

Other Special Situation

Filing with Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Update on Progress and Fina...

Quantitative Data

Quantitative Data Filing

Financial Update

Annual Meeting Approval

Quantitative Data

Financial Statements and Ea...

Financial Statements and Ea...

Reverse Stock Split

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

External Links:

On June 16, 2025, Lixte Biotechnology appointed Geordan Pursglove as CEO and Chairman under a three-year contract with a salary of $240,000 and a stock option to purchase 350,000 shares, conditional on financing. Bastiaan van der Baan also transitioned to President and Chief Scientific Officer, with amendments to his previous agreement regarding stock options.

AI Assistant

LIXTE BIOTECHNOLOGY HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.